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Abstract
Background Potential treatment-related neurotoxicity and
the indolent course of the disease mainly feed the contro-
versy concerning the optimal timing of surgery and
radiotherapy in meningioma patients.
Object To quantify the additional negative effects of
conventional radiotherapy compared to surgery alone on
neurocognitive functioning and health-related quality of
life (HRQOL) in patients with WHO grade I meningiomas.
Methods Neurocognitive functioning and HRQOL (SF36,
EORTC-BCM20) were assessed in consecutive patients
(1999–2005) with WHO grade I meningiomas at least
1 year after surgical treatment in two centers for brain
tumor patients. Subsequently, we selected all patients who
underwent surgery and conformal external beam fractioned
radiotherapy (n = 18) and matched these patients for age,
sex, and educational level with the same number of patients
who had had surgery only (n = 18), as well as with the
same number of healthy controls.
Results No significant differences in neurocognitive
functioning were found between the two meningioma
patient groups; however, even meningioma patients who
were treated with surgery only had a significantly lower
neurocognitive functioning than healthy controls.
Meningioma patients who were treated with surgery and
radiotherapy had significantly lower HRQOL scores than
meningioma patients who were treated with surgery only,
who had HRQOL ratings comparable with healthy
controls; these differences, however, disappeared after
correction for the duration of disease.
Conclusions In contrast with conventional thinking, long-
term neurocognitive functioning was significantly impaired
in our meningioma patients. Additional radiotherapy fol-
lowing surgery, however, does not have additional delete-
rious effects on neurocognitive outcome in these patients.
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RE Role limitation caused by emotion problems
MH Mental health
PCS Physical component scale
MCS Mental component scale
Introduction
Meningiomas (i.e. primary tumors arising from the dural
coverings of the brain) are the most common primary
non-glial brain tumors, accounting for 13–26% of all
primary brain tumors. Meningiomas have an annual
incidence of approximately 6 per 100,000 population [1].
Histological grading of meningiomas is based upon the
current World Health Organization (WHO) classification
[2]. About 90% of the meningiomas are benign, which
corresponds to WHO grade I. Atypical meningiomas
(WHO grade II) make up 5–7%, and anaplastic variants
(WHO grade III) arise in 1–3% of the cases [3].
Surgical excision of the tumor and its dural base is the
usual initial treatment, particularly in easily accessible
tumors localized on the outer brain surface or at the cere-
bral falx between both hemispheres (so-called convexity
tumors). Radiotherapy has clinical benefits when tumor
histology reveals atypia or anaplasia (WHO grade II and
III). Radiotherapy also reduces the risk of local recurrence
of grade I tumors after a subtotal resection. However, the
clinical value and optimal timing of radiotherapy after (in-)
complete surgery or after recurrence remains a matter of
debate [4–7].
The controversy on the choice and timing of
radiotherapy can be attributed to a lack of knowledge
regarding its side effects. The few available data indicate
that about 30% of meningioma patients experience
severe long-term cerebral sequelae, mostly neurocogni-
tive deficits [8–10]. It is unclear, however, whether this
is due to pre-treatment brain damage by the tumor itself,
to surgery, to radiotherapy, or to a combination of these.
For other types of primary brain tumors it is known that
neurocognitive deficits in patients can be attributed to a
combination of these factors [11, 12]. Complications of
treatment, especially when resulting in neurocognitive
dysfunction, have a great impact on patients and their
proxies. Unfortunately, little is known about the effect of
different treatment options on the frequency and severity
of neurocognitive dysfunction in meningioma patients.
More information on this issue will lead to improved
understanding of the complaints of meningioma
patients, and offer support in the choice and timing of
treatment.
The present study aimed to determine the effect of
additional radiotherapy on neurocognitive functioning. We
hypothesized that additional radiotherapy in meningioma
patients will have a cumulative negative effect on neuro-
cognitive functioning and health-related quality of life
(HRQOL) compared with surgery only. To put neurocog-
nitive functioning and HRQOL of meningioma patients
who underwent surgery only in perspective, we compared




This study is part of a two-center, retrospective investi-
gation into the prevalence and severity of neurocognitive
problems in meningioma patients. For the present study
we interviewed all adult (>18 years) patients with WHO
grade I intracranial meningiomas, who were treated ei-
ther with surgery only (RT–), or with surgery and
adjuvant external beam conformal radiotherapy (RT+) at
two tertiary referral centers for brain tumor patients in
Amsterdam (i.e. the Academic Medical Center and the
VU University Medical Center) from 1999 through 2005.
In these centers, the decision to treat meningioma
patients with radiotherapy after surgery is always made
on basis of localization and size of the tumor. In some
patients the tumor could only be resected partially
because of the localization of the tumor, mainly skull-
base meningiomas. In these patients and in patients with
a recurrence after one or more surgical resections,
additional radiotherapy was given. Patients must have
undergone their last treatment at least 1 year previously.
Exclusion criteria were: treatment by stereotactic radio-
therapy, or the presence of two or more of the following
conditions: cerebrovascular pathology, presence of other
tumors of the nervous system, congenital malformations
of the nervous system, multiple sclerosis, Parkinson’s
disease, organic psychosis (other than dementia), and
schizophrenia. Also excluded were patients with optic
nerve meningiomas. Patients had to have sufficient
command of the Dutch language to be able to carry out
the neurocognitive tests. The medical ethics committees
of both medical centers approved the study protocol.
Eligibility was checked by medical chart review and, if
necessary, with the general practitioner.
A total 89 patients with intracranial WHO grade I
meningiomas were recruited, of whom 61 (69%)
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underwent surgery, 4 received radiotherapy only (4%), 21
had surgery and adjuvant conformal external beam radio-
therapy (24%) and 3 received neither surgical treatment nor
radiotherapy (3%). We invited patients by letter. Informed
consent procedures preceded patients’ agreement to
participate. Eventually, 11 eligible patients declined to
participate; of these patients, 6 underwent surgery, 3
underwent surgery and subsequent radiotherapy, and 2 had
not received therapy. The main reason for refusal was that
participation was too burdensome. In total 94% of the
meningioma patients who underwent RT– and 83% of the
RT+ patients were tested at home; the remaining patients
were tested in the hospital. Clinical data obtained from
medical chart review at entry, included tumor characteris-
tics [histology, location (convexity, tentorium/falx, skull
base, orbit), size, hyperostosis, and edema]. The preoper-
ative tumor volume was estimated by assuming an ellipsoid
of the orthogonal tumor diameters x, y, and z on CT-scan
and/or MRI:
Tumor volume ¼ 4=3p  ð1=2x  1=2y  1=2zÞ
Tumor area ¼ p  ð1=2x  1=2yÞ
Before neuropsychological testing, the patients com-
pleted a questionnaire regarding sociodemographic data
(including age, sex, and educational level) and a ques-
tionnaire on HRQOL, and epilepsy and its treatment
[13].
For this study, we selected all patients from the database
who underwent surgery and adjuvant radiotherapy (RT+)
and matched these patients with the same number of
patients from the database who underwent surgery only.
Patients were matched for age, sex, and educational level.
Healthy controls
In addition to RT– and RT+ patients, normative data of
healthy controls were used as an additional anchor to
interpret the results. Healthy controls were drawn from a
large, cross-sectional study of the biological and psy-
chological determinants of neurocognitive aging, the
Maastricht Aging study [14]. We matched this control
group with RT– patients with respect to age, sex, and
educational level. Educational level was assessed by a
Dutch scoring system consisting of an eight-point scale,
ranging from unfinished primary education (level 1) to
university education (level 8). In order to compare
HRQOL outcomes, healthy controls matched for age,
sex, and educational level were drawn from a nationwide
study that aimed to translate, validate, and generate
normative data on the Short-Form Health Survey (SF-36)
for use among Dutch-speaking residents of the Nether-
lands [15].
Study measures
Health-related quality of life
We assessed patients’ overall degree of physical function
with the Karnofsky Performance Status (KPS) scale, which
is frequently used in clinical cancer research. Scores range
from 0 (lowest score) to 100 (highest level) [16]. The
ability to perform daily activities was assessed with the
Barthel Activities of Daily Living index [17]. The index
consists of ten items (assessing continence of bowel and
bladder, grooming, toilet use, feeding, transfer, mobility,
dressing, climbing stairs, and bathing); higher scores
indicate good functional independence.
Neurological functioning was scored with the neuro-
logical functioning scale developed by Order et al. [18].
Scores for this scale range from 1 to 4, with higher
scores indicating intact neurological functioning. For
self-reported HRQOL we used the MOS Short-Form
Health Survey (SF-36) [19]. The SF-36 is composed of
36 items, organized into eight multi-item scales assessing
physical functioning (PF), role limitation caused by
physical health problems (RP), bodily pain (BP), general
health (GH), vitality (VT), social functioning (SF), role
limitation caused by emotional problems (RE), and
mental health (MH). Rough scores are converted linearly
to 0–100 scales, with higher scores representing better
levels of functioning. In addition, we calculated two
higher-order compound scores, a physical component
scale (PCS) and a mental component scale (MCS). The
BCM-20 questionnaire was used to assess additional
health problems associated specifically with meningioma
and its treatment [20]. Of the 20 BCM items, 13 are
organized into 5 subscales assessing future uncertainty,
visual disorder, motor dysfunction, communication defi-
cit, and emotional distress. The remaining seven items
assess other disease symptoms and side-effects of treat-
ment prevalent among patients with brain tumors,
including headaches, seizures, drowsiness, hair loss,
itching, weakness of the legs, and lack of bladder con-
trol. Since emotional status was already assessed by the
SF-36, the 4-item emotional distress scale of the BCM-
20 was not analyzed.
Neurocognitive functioning
Because of the different causes and severity of neurocog-
nitive problems, we used a wide range of tests to assess
neurocognitive functions. Neurocognitive functions refer to
an individual’s ability to perceive, store, retrieve, and use
sensory and perceptual information from the environment
and past experience, and to such mental activities as
planning and organizing. A battery of standard tests was
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used to assess neuropsychological status. The total time
required to complete the battery was approximately
60 min. Appendix 1 provides detailed information on this
test battery.
Statistical analysis
Statistical analyses were performed with SPSS (version
11.0). Chi-square tests were used to match the RT– patients
with healthy controls for sex. Chi-square tests were also
used to show differences in pathological features (e.g.
meningothelial, transitional) between RT– and RT+
patients. RT+ meningioma patients were compared with
RT– meningioma patients, and RT– meningioma patients
were compared with healthy controls for HRQOL and
neurocognitive functioning. Student’s t test was used for
independent samples to determine whether neurocognitive
function and HRQOL of meningioma RT+ patients
differed from that of meningioma RT– patients. Student’s t
test was also used to determine whether neurocognitive
functioning and HRQOL of RT– meningioma patients
differed from that of healthy controls. The level of
significance was set at P < 0.05.
Results
Patients’ characteristics
Included were 18 patients who underwent surgery followed
by radiotherapy (RT+) and these patients were matched
with 18 patients who underwent surgery only (RT–).
Table 1 presents the sociodemographic characteristics of
the RT– and the RT+ patients. Regarding the RT+ patients,
adjuvant radiotherapy consisted of conformal external
beam fractionated radiotherapy; the radiation dose was
50.4–54.0 Gy in 1.8–2.0 Gy per fraction, five fractions per
week, using 6–10 MeV photon beams. None of the 36
patients had clinical or radiological signs of tumor pro-
gression.
The near optimal levels for neurological functioning
(Order scale) and daily living (Barthel index) did not differ
significantly between the two groups, although RT+
meningioma patients were significantly more limited in
their physical functioning (PCS) than RT– patients. In RT–
meningioma patients, more tumors were localized in the
convexity and less at the skull base than in RT+ menin-
gioma patients. There were no significant differences in
tumor volume, nor in pathology subgroups, between RT–
and RT+ patients. Although, follow-up time was
significantly different between RT– and RT+ patients, no
differences were seen in time since last treatment.
Neurocognitive functioning
Data on neurocognitive functioning and HRQOL are given
in Tables 2, 3 and 4. RT+ patients did not have a signifi-
cantly impaired performance on the Line Bisection test
compared to RT– patients, which excludes a major midline
deviation (Table 4). In the tests for memory, especially
AVLT total recall, AVLT max and AVLT delayed recall,
RT– scored significantly worse compared with healthy
controls. RT+ meningioma patients did not score differ-
ently from RT– meningioma patients on most tests mea-
suring attention and executive functioning. RT+
meningioma patients were slightly faster on Stroop card I
and II, but slower on Stroop card III. For RT– meningioma
patients no clear differences were seen, except that Stroop
card II took more time compared with healthy controls.
RT+ patients performed worse on the Fluency test. RT+
patients took less time to accomplish the CST A and CST B
test but took more time on the CST C test compared with
RT– meningioma patients. RT– meningioma patients nee-
ded more time to complete for the CST tests compared with
healthy controls.
Table 1 Sociodemographic and clinical characteristics of the study
patients
Patient groups Surgery only
(n = 18)
Surgery plus
radiotherapy (n = 18)
Variables M SD M SD P*
Characteristics
Mean age in years 62.6 11.8 63.3 10.6 0.424
Male:female ratio 1:7 1:8
Educational levela 3.28 2.1 3.17 1.3 0.425
Mean IQ 99.2 17.4 95.1 16.0 0.236
Years since diagnosisa 3.0 1.7 7.6 6.3 0.013
Years since last treatmenta 3.3 2.0 3.3 1.9 0.982
Functional/performance status
Karnofskya 82.8 19.6 71.1 18.4 0.038
Barthela 17.2 1.4 17.2 1.6 0.408
Ordera 3.7 0.5 3.8 0.4 0.131
Number of tumorsa 1.0 0.0 1.5 1.2
Volume of tumor (ml3)a 23.5 19.3 39.4 43.5 0.202
Area of tumor (cm2)a 11.0 6.8 15.3 12.0 0.230
Pathologic features
Meningothelial 6 9 0.310
Fibroblastic 1 0.310
Transitional 2 0.146
Not further classified 10 6 0.180
Unknown 2 0.146
a Mean test scores
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Health-related quality of life
Compared with RT– patients, RT+ meningioma patients
scored less well on self-reported HRQOL. RT+ meningi-
oma patients had significantly impaired physical function-
ing (PF), more role limitations caused by physical health
problems (RP), lower Vitality (VT), and lower scores on
the Physical Component Scale (PCS). These differences,
however, disappeared after correction for the duration of
disease. When RT– patients were compared with healthy
controls, no significant differences were seen. Scores of the
BCM-20 showed no significant differences between
RT– and RT+ meningioma patients (Table 3).
Discussion
In this study, no significant differences were found in
neurocognitive functioning between WHO grade I menin-
gioma patients that underwent surgery only, and patients
that received additional radiotherapy; however, even
patients who were only treated surgically had a signifi-
cantly lower neurocognitive functioning than healthy
controls. The most profound neurocognitive disturbances
were seen in memory tasks. Meningioma patients who
were treated with surgery and radiotherapy had signifi-
cantly lower HRQOL scores than meningioma patients
who were treated surgically only, who had HRQOL scores
comparable with healthy controls; these differences,
however, disappeared after correction for the duration of
disease.
Very few studies have been published on neurocognitive
functioning of meningioma patients. Tucha et al. [21]
examined neurocognitive functioning before and shortly
after surgery for a frontal meningioma. Surgery improved
neurocognitive functioning but, compared with healthy
controls, significant postoperative neurocognitive deficits
remained, particularly a lowered attention span and de-
creased executive functions. These latter data agree with
our long-term results at least 1 year after treatment. Unlike
differences in histology and biology of meningioma, some
striking results are similar to those reported in previous
studies in patients with other types of primary brain tumors
[22, 23]. We found neurocognitive disturbances in our
meningioma patients similar to those in glioma patients
and, similarly, radiotherapy was not associated with poorer
neurocognitive outcome.
Table 2 Scores on the HRQOL test of RT– meningioma patients, RT+ meningioma patients, and healthy controls
Variables RT– patients (n = 18) RT+ patients (n = 18) Healthy controls (n = 18)
M SD M SD P* M SD P
Physical functioning (PF) 72.5 32.7 54.7 54.47 0.047 73.9 25.2 0.381
Role physical (RP) 61.1 43.2 33.8 38.5 0.032 63.2 34.4 0.476
Bodily pain (BP) 66.6 40.1 56.3 23.9 0.184 61.9 24.6 0.281
General health (GH) 60.7 25.0 45.2 27.2 0.050 64.8 17.8 0.294
Vitality (VT) 60.9 31.3 44.4 21.0 0.039 61.7 18.0 0.442
Social functioning (SF) 69.5 33.8 66.7 24.3 0.388 70.6 25.7 0.472
Role emotional (RE) 77.8 41.1 72.5 42.9 0.364 75.0 35.5 0.314
Mental health (MH) 71.6 23.8 70.8 22.7 0.461 69.6 19.3 0.468
PCS 44.8 13.2 33.2 11.0 0.007 45.4 11.6 0.335
MCS 51.8 11.6 50.9 13.0 0.421 48.7 12.2 0.323
Data are mean (M) and standard deviation (SD)
PCS physical component score, MCS mental component score






M SD M SD P*
Future uncertainty 23.4 26.2 28.2 25.9 0.248
Visual disorder 15.0 22.2 28.4 28.3 0.065
Motor dysfunction 17.0 26.1 27.2 25.3 0.126
Communication deficit 20.9 30.4 19.1 21.2 0.421
Headaches 23.5 22.9 40.7 42.1 0.073
Seizures 5.9 17.6 13.0 28.3 0.192
Drowsiness 21.6 31.0 33.3 32.3 0.141
Bothered by hair loss 5.9 13.1 14.8 26.1 0.107
Bothered by itching skin 23.5 34.9 24.1 37.6 0.433
Weakness of legs 11.8 23.4 24.1 33.9 0.112
Difficulty controlling bladder 13.7 23.7 18.5 32.8 0.313
Data are mean (M) and standard deviation (SD)
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Despite major neurocognitive deficits, we found no
impaired HRQOL in patients who had surgery only.
Discrepancies between HRQOL and neurocognitive
functioning have been described for other patient groups
[24, 25]. There may be limitations in the ability of patients
with brain disease and resulting cognitive disturbance to
appraise their own situation.
In contrast, we did find a decreased HRQOL in patients
who had surgery plus radiotherapy, particularly in the
physical component of the SF-36. It may be tempting to
attribute the lower physical performance and quality of life
to progressive radiation damage in these patients. How-
ever, the reverse is more plausible, namely that patients
needing adjuvant radiotherapy had larger and more com-
plex meningiomas that inherently cause more cerebral
damage, perhaps even aggravated by more extensive
surgery. Furthermore, we should keep in mind that the
impending threat of tumor recurrence and heavier
treatment imposes a psychological burden with resultant
anxiety, depression, or fatigue, which can also negatively
affect the patient’s neurocognitive function [22]. Patients
who had surgery only had a much shorter disease history
(on average 3.0 years) than patients who had surgery plus
radiotherapy (on average 7.6 years), frequently after
repeated earlier surgery. After correction for time after
primary diagnosis (post hoc analysis), no significant
differences were seen for HRQOL between RT– and RT+
meningioma patients. Most likely, the impaired HRQOL is
therefore associated with a longer disease history.
Several limitations of this study should be mentioned.
First of all, because we used a retrospective design, we lack
a baseline pretreatment assessment. It is possible that the
RT+ patients were functioning at a much higher HRQOL
level before radiotherapy compared to the RT– patients.
This would imply that the outcomes of post-treatment
HRQOL should be seen in a different perspective.
However, as the decision to add radiotherapy was solely
based on surgical grounds, a selection bias on the basis of
Table 4 Scores on the neuropsychological tests of RT– meningioma patients, RT+ meningioma patients, and healthy controls
Variables RT– patients (n = 18) RT+ patients (n = 18) Healthy RT– controls (n = 18)
M SD M SD P* M SD P**
Perception
Line bisection-HD 0.12 2.0 0.38 2.3 0.358 5.5%a b b
Line bisection-VD 2.46 1.5 1.42 2.2 0.058 27.8%a b b
Memory
AVLT trial 1 (nc) 4.2 2.2 4.2 1.5 0.500 4.4 2.4 0.414
AVLT total recall (nc) 33.1 13.0 30.7 10.7 0.253 42.0 11.8 0.019
AVLT delayed recall (nc) 6.7 4.0 6.1 2.8 0.232 9.0 3.2 0.037
AVLT delayed recognition 13.1 2.2 13.2 1.8 0.467 13.9 2.0 0.137
AVLT delta score 4.8 2.0 4.1 2.2 0.135 6.6 2.5 0.012
AVLT max (nc) 9.1 3.4 8.3 2.7 0.227 11.0 2.7 0.019
WMT slope 17.2 9.5 16.1 10.9 0.378 15.2 5.6 0.223
WMT intercept 33.6 14.3 39.9 17.8 0.133 27.5 6.5 0.056
Attention and executive function
SCWT card I (s) 55.1 21.8 50.9 17.1 0.268 53.1 8.5 0.360
SCWT card II (s) 72.3 28.4 71.2 14.8 0.446 64.0 9.0 0.121
SCWT card III (s) 111.8 56.0 124.7 42.0 0.230 110.8 22.2 0.270
SCWT interference (%) 86.7 62.3 95.7 37.1 0.311 89.5 29.6 0.234
Fluency (nc) 20.7 8.9 18.9 6.2 0.246 22.3 5.7 0.269
CST A (s) 38.8 39.0 31.6 10.0 0.235 23.1 5.2 0.051
CST B (s) 50.7 71.5 40.7 15.7 0.287 24.5 5.1 0.065
CST C (s) 53.2 43.6 55.8 26.5 0.417 45.0 21.6 0.162
Motor component (s) 9.4 9.5 9.2 4.3 0.475 6.2 1.5 0.087
Means (M) and standard deviations (SD) represent estimated means based on corrections for age and education for RT– and RT+ patients. Means
and standard deviations for healthy control are observed scores
* P-values of univariate F tests for RT– and RT+ patients corrected for age and educational differences
** P-values of t tests comparisons between RT– patients and healthy age, sex, and education matched controls
a Percentage of meningioma patients who deviated >2 SD of healthy controls
b Age, sex, and education matched data unavailable
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pre-existent HRQOL level is very unlikely. The anatomical
distribution of meningiomas differs between both patient
groups. As differences in localization might be associated
with differences in vulnerability for the neurocognitive side
effects of radiotherapy, e.g. higher risks for tumors
involving eloquent brain areas, this should be taken into
account when interpreting the neurocognitive scores of
both groups. The historical cohort study design may have
resulted in a selection bias and confounding bias. For
example, patients with severely debilitating disease that
precluded testing were excluded from analyses. Also, the
number of patients is relatively small which might have
influenced the results. On the other hand, this small number
enabled to correct for tumor localization and use of anti-
epileptic drugs, factors that are known to influence neu-
rocognitive functioning [22].
In conclusion, the results of our study strongly suggest
that the addition of radiotherapy has no significant detri-
mental impact on late neurocognitive functioning in
meningioma patients. Our data also indicate that the neg-
ative effects on cognition are due to the tumor itself or to
surgery. Further study with a prospective study design
including baseline scores for QOL and neurocognitive
functioning will be necessary to draw definite conclusions
regarding the extent and causality of neurocognitive dis-
turbances in meningioma patients.
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The Dutch Adult Reading Test (DART) [26]. The Dutch version of the
New Adult Reading Test provides a measure of premorbid capacity
based on verbal ability.
Perception
Line Bisection Test [27]. This test is a device for measuring unilateral
neglect, which is usually a sequel of massive right hemisphere
lesions. Noticeable errors are most often made by patients with
visual field defects who tend to underestimate the side of the line




Auditory Verbal Learning Test (AVLT) [28]. This version of the Rey
Auditory Verbal Learning Test calls for various aspects of verbal
learning and recall. Measures used for analysis are: memory
performance on trial 1 as indicator of immediate recall, total recall
after five trials, delayed recall and recognition after 20 min as
indicators of memory consolidation into long-term memory, and a
delta score as a measure of learning capacity.
Working Memory Task (WMT) [29]. This task is designed to measure
the speed of memory processes. The underlying principle is that the
extra time needed to complete a test in which there is a stepwise
increase in the amount of information to be kept in memory, is a
measure of the ease at which information is processed in working
memory. Capacity is measured by using the slope and intercept as a
function of the number of letters to be kept in working memory.
Attention and executive function:
Stroop Color-Word Test (SCWT) [28]. This test is a selective attention
task aiming at measuring interference susceptibility and consists of
three subtasks with increasing task complexity.
Categoric Word Fluency [30]. This is a task requiring the generation
of words from specific semantic categories (animals) within a
limited time.
Concept Shifting Test (CST) [31]. This test, which has two conditions
of complexity, predominantly measures functions associated with
executive function, especially visual scanning and conceptual
tracking. The motor component of this task is measured by three
dummy conditions in which no neurocognitive capacity except for
graphomotor speed is required.
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